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MD, K. HerrmA.K. Buck, MD,
Abstract: Tyrosine kinase inhibitors (TKIs) such as vandetanib have
shown clinical effectiveness in advanced medullary thyroid cancer
(MTC). During TKI treatment, fluctuations in the tumor markers
carcinoembryonic antigen (CEA) and calcitonin (CTN) are frequently
observed. Their role for treatment monitoring and the decision-making
process has not been fully elucidated yet.
Twenty-one patients (male, 16, female, 5; mean age, 49 13 years)
with progressive MTC receiving vandetanib (300 mg orally per day)
were considered. Tumor restaging was performed every 3 months
including contrast-enhanced computed tomography (CT). Response
was assessed according to recent criteria (Response Evaluation Criteria
in Solid Tumors, RECIST 1.1). Additionally, CEA and CTN were
measured at the day of CT imaging and alterations observed in tumor
markers were compared to respective imaging findings (partial
response, PR; stable disease, SD; progressive disease, PD).
During long-term follow-up (510 350 days [range, 97–1140
days]), CTN and CEA levels initially dropped in 71.4% and 61.9%
of the patients followed by fluctuations in serum marker levels. A rise in
CTN 39.5% between 2 subsequent measurements (defined by ROC
analysis) had a sensitivity of 70.6% and a specificity of 83.2% in
predicting PD with an accuracy of 82.0% (area under the
curve (AUC), 0.76). Oscillations in CEA levels were not predictive
for PD.relle, C. Reiners, ann, MD,
d C. Lapa, MD
(Medicine 94(45):e2016)
Abbreviations: AUC = area under the curve, CEA =
carcinoembryonic antigen, CT = computed tomography, CTN =
calcitonin, MTC = medullary thyroid carcinoma, NPV = negative
predictive value, PD = progressive disease, PPV = positive
predictive value, RECIST = Response Evaluation Criteria in
Solid Tumors, ROC = receiver operating characteristic, TKIs =
tyrosine kinase inhibitors.
INTRODUCTION
M edullary thyroid carcinoma (MTC) is a neuroendocrinetumor of the parafollicular cells of the thyroid gland that
secretes both calcitonin (CTN) and carcinoembryonic antigen
(CEA). It accounts for approximately 5% of thyroid carci-
nomas.1,2 Due to its origination, MTC is not iodine-responsive
and surgery remains the only curative option in early stages.3
Patients with unresectable local disease and/or distant metas-
tases are candidates for systemic treatment.
Recently, the tyrosine kinase inhibitors (TKIs) vandetanib
and cabozantinib have been approved for use in MTC.4
Although almost all patients respond initially with significant
decreases in serum tumor marker levels during the first weeks
after treatment initiation,5 tumor escape to alternate pathways
frequently occurs.6 Therefore, early detection of progressive
disease (PD) is crucial, facilitating treatment with alternative
TKIs in case of apparent resistance to treatment. Serum tumor
marker assessment, including measurement of both CTN and
CEA, is a simple and well-established means of disease
monitoring; however, the role of their kinetics in the long-term
course of TKI treatment has not been fully elucidated yet.
Fluctuations in both CTN and CEA without clinical relevance
have recently been described.5 Given the rising importance and
more widespread clinical use of TKI in MTC patients outside
the setting of controlled clinical trials, detection of the appro-
priate time point to modify the treatment in individual patients
due to changes in serum tumor markers will be of growing
importance in a clinical setting.
Therefore, we assessed the value of both CEA and CTN for
prediction of tumor progression in MTC patients treated with
vandetanib.
METHODS
Between April 2007 and April 2013, 21 patients (16 male, 5
female; mean age, 49 13 years) received vandetanib (300 mg
orally per day) due to advanced MTC on a compassionate use
basis at the University Hospital of Würzburg, Germany. Allumber of previous treatments including
.3%), chemotherapy (n¼ 3/21; 14.3%),
¼ 3/21; 14.3%). All patients gave written
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#1 M 38 0 24 Sporadic Metastatic LN, lung None Unknown
#2 M 69 0 9 Sporadic Metastatic LN, bone, lung Surgery Negative
#3 M 62 0 16 Sporadic Metastatic liver Surgery Negative
#4 M 40 2 10 Sporadic Metastatic LN, bone,
liver, lung
Surgery Negative
#5 F 57 1 25 Sporadic Metastatic Liver, lung Surgery Unknown
#6 F 59 0 11 Sporadic Metastatic LN, liver Surgery, CTx,
somatostatin, TACE
Negative
#7 M 41 1 12 Sporadic Metastatic LN, lung Surgery, CTx Unknown
#8 M 50 1 13 Sporadic Metastatic LN, lung Surgery Unknown
#9 M 25 0 15 Hereditary Metastatic LN, lung Surgery, RTx, PRRT Unknown
#10 M 63 1 7 Sporadic Metastatic LN Surgery Unknown
#11 F 20 0 6 Sporadic Metastatic LN, liver Surgery Negative
#12 M 57 0 6 Hereditary Metastatic bone, liver, lung Surgery, TACE Positive
#13 M 40 1 11 Sporadic Metastatic LN, lung Surgery, CTx Unknown
#14 M 47 1 4 Sporadic Metastatic Lung Surgery Negative
#15 M 40 0 8 Sporadic Metastatic LN, bone, liver Surgery Negative
#16 F 40 2 15 Sporadic Metastatic LN, bone, liver Surgery Negative
#17 F 35 1 20 Sporadic Metastatic LN, lung Surgery Negative
#18 M 36 0 7 Sporadic Metastatic LN, liver, lung Surgery, RTx, PRRT Unknown
#19 M 70 0 6 Sporadic Locally advanced — Surgery Unknown
#20 M 59 0 2 Hereditary Metastatic LN Surgery Positive
#21 M 30 15 Sporadic Metastatic LN, liver, lung Surgery, RTx Negative
CTx¼ chemotherapy; ECOG¼Eastern Cooperative Oncology Group; f¼ female; LN¼ lymph node; m¼male; PRRT¼ peptide receptor
iati
Werner et al Medicine  Volume 94, Number 45, November 2015informed consent to the therapeutic and diagnostic procedures.
As this study is a retrospective analysis of single-center data, the
local ethic committee has waived the need for further approval.
Detailed patient information including clinical factors is given in
Table 1.
Tumor Response Assessment
Onset of tumor progression (PD) was defined according to
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
based on computed tomography (CT) performed every 3 months
(9 6 examinations per patient).7 RECIST measurements were
confirmed by both an attending nuclear medicine physician and
radiologist. All scans were performed using a 64-slice spiral CT
(SOMATOM Sensation 64, Siemens Medical Solutions, Erlan-
gen, Germany) with intravenous contrast enhancement (care
dose modulation with a quality reference of 210 mAs, 120 kV, a
512 512 matrix, 5 mm slice thickness) or without (40 mAs,
120 kV, a 512 512 matrix, 5 mm slice thickness), covering the
base of the skull to the proximal thighs.
Tumor Markers
CEA (mg/L) and CTN (pg/ml) were measured at baseline
and at each restaging time point using dedicated radioimmuno-
assays (electro-chemiluminescence immunoassay, DPC-Bier-
mann-Siemens, Bad Nauheim, Germany [CEA] and
radionuclide therapy; RET¼ rearranged-during-transfection; RTx¼ rad
Health Organization.immunoluminometric assay, DPC-Biermann-Siemens, Bad
Nauheim Germany [CTN]). Intra- and interassay comparisons
were performed regularly. The upper reference-limit for CTN is
2 | www.md-journal.com18.2 pg/ml and for CEA 5.0 mg/l (nonsmokers) and 6.5 mg/l
(smokers), respectively.
Analysis and Statistics
A potential relationship between imaging findings and
serum tumor marker levels was investigated. Statistical analyses
were performed using PASW Statistics software (version 22.0;
SPSS, Inc., Chicago, IL). Quantitative values were expressed as
mean standard deviation and range as appropriate. The 2-tailed
paired Student t test was used to compare differences between 2
dependent groups, and the 2-tailed independent Student t test for
differences between independent groups. A P-value of less than
0.05 was assumed to be statistically significant. Cut-off values for
the prediction of imaging-based PD were determined for CTN by
receiver operating characteristic (ROC) analysis.8 Additionally,
in order to test a correlation between tumor markers and clinical
factors, Pearson correlation was performed. A P-value of 0.05 or
less was considered to be statistically significant. Other obser-
vations described are of descriptive nature.
RESULTS
Patients
At baseline CT, performed before initiation of therapy with
vandetanib, all patients presented with progressive metastatic/
locally advanced disease. Metastatic sites included lymph nodes
on therapy; TACE¼ transarterial chemoembolization; WHO¼World(n¼ 16/21; 76.2%), lung (n¼ 13/21; 61.9%), liver (n¼ 10/21;
47.6%), and bone (n¼ 5/21, 23.8%). Mean follow-up of sub-
jects was 510 350 days (range, 97–1140 days). Information
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
on RET mutation status was available in 12/21 patients (57.1%).
Medicine  Volume 94, Number 45, November 2015A germline RET mutation was present in 2/12 subjects, whereas
the remaining 10/12 patients tested were negative for both
germline and sporadic mutations.
Tumor Marker Kinetics
Before treatment, all but 1 patient (Patient #19) had
elevated CTN and CEA levels with median baseline values
of 13,657 pg/ml (range, 2.5–135,100) and 458 mg/L (range,
2.8–1014.8), respectively. An initial decrease of CTN (at 3
months) was recorded in 15/21 (71.4%) of the subjects, whereas
6/21 (28.6%) patients did not show biochemical response to
therapy. In the course of treatment, CTN levels dropped to a
nadir in 14/21 (66.6%) with a median drop of 45.7% (range, 11–
98%). The nadir was reached after 268 208 days (range, 5–
777 days). Thereafter, fluctuations in CTN could be observed in
all 14 subjects, temporarily exceeding baseline in 9/14 cases
(64.3%). Of the remaining 7 patients, 5 presented with con-
tinuously declining, 2 with continuously rising tumor marker
levels during follow-up.
At 3 months, CEA levels decreased in 13/21 subjects
(61.9%). In the course of vandetanib treatment, CEA levels
dropped to a nadir in 7/21 (33.3%) subjects (median drop of
18.9% [range, 6–56%]). The nadir was reached after 368 273
FIGURE 1. Time curves (of every patient) for calcitonin (CTN) and ca
disease or partial response; left) or progressive disease (right). Almost
initiation of treatment with vandetanib, whereas the patients with long
and CEA levels (left column), the subjects with true progressive disease
distinction is more prominent for CTN than for CEA.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.days (range, 5–776 days). Thereafter, alterations were recorded
in all of these 7 patients with CEA spiking above baseline in 1/7
(14.1%). Of the remaining 14 patients, 4 demonstrated con-
tinuously increasing, 10 with continuously decreasing tumor
marker levels.
Tumor Response
During a follow-up period of 17 11.7 months, 13/21
(61.9%) patients could be classified as having stable disease
(SD) and 2/21 (9.5%) achieved a partial response (PR) accord-
ing to RECIST. On average 517 461 days (range, 97–1449
days) after pretherapeutic baseline CT, 6/21 (28.6%) patients
(28.5%) developed PD. None of the patients died from their
cancer within follow-up. Of note, in contrast to the patients with
controlled disease, CTN demonstrated a more continuous pat-
tern in tumor marker increases in the subjects with PD. This
pattern was not as distinct for CEA. The respective time curves
of CTN and CEA levels for both patient groups (progressive vs.
controlled) are given in Figure 1.
Correlation of Tumor Markers With Age, Sex,
Tumor Markers in Vandetanib-Treated MTCand Imaging Findings
Changes in CEA moderately correlated with changes in
CTN (r¼ 0.405, P< 0.001), independent from age and sex.
rcinoembryonic antigen (CEA) for patients with controlled (stable
all patients display an initial decline in serum tumor markers after
-term disease control just present with transient fluctuations in CTN
experience a continuous rise in tumor markers (right column). This
www.md-journal.com | 3
TABLE 2. Overview of Results of ROC Analysis for CTN
Cut-Off
Value Sensitivity Specificity Accuracy PPV NPV
14.5 82.4 70.2 71.3 22.6 97.3
39.5 70.6 83.2 82.0 30.8 96.4
CTN¼ calcitonin; NPV¼ negative predictive value; PPV¼ positive
Werner et alROC Analysis
Whereas changes in CEA levels were not predictive for
PD, a rise in CTN with a cut-off value of 14.5% predicted
morphologic progression with a sensitivity of 82.4% and a
specificity of 70.2%, resulting in an accuracy of 71.3% (area
under the curve (AUC)) 0.76; positive predictive value (PPV),
22.6%; negative predictive value (NPV), 97.3%. A cut-off value
39.5% yielded a sensitivity of 70.6% and a specificity of
83.2% with an accuracy of 82.0% (PPV, 30.8%, NPV, 96.4%;
Table 2; Fig. 2).
DISCUSSION
The clinical utility of both tumor markers CTN and CEA in
the management of MTC is well accepted.9 RET inhibition
therapy using TKIs has been reported to be associated with an
initial rapid decline in tumor marker levels and a subsequent
predictive value; ROC¼ receiver operating curve.
All results are given in %.phase of oscillation without necessarily indicating relapse, resist-
ance to treatment or PD.5 Controlling a pathway responsible for
CTN gene transcription and protein secretion, RET inhibitors
FIGURE 2. Receiver operating characteristic (ROC) curves of cal-
citonin for prediction of progressive disease. Area under the
curve¼0.76.
4 | www.md-journal.commay influence serum tumor marker levels without any reference
to tumor burden or growth inhibition. However, true tumor escape
cannot always be excluded. In our cohort enrolling patients with
advanced disease not adequately responding to 1st or 2nd line
therapy, PD developed more than 1 year after initiation of TKI
therapy. Given the increasing use of this class of drugs, the rising
number of long-term treatments and the growing numbers of
RET- or other kinase-directed medications, it is important to
discern the optimal time point for further work-up and, poten-
tially, a change in treatment management.
In our study comprising 21 MTC vandetanib treated MTC
patients, a rise in CTN 40% predicted PD (as detected by CT)
with an accuracy of 82%. This cut-off value might serve treating
physicians outside the scenario of controlled studies as an
indicator when to order further diagnostic work-up or when
to consider a change in patient management. Short-term fluctu-
ations lower than this cut-off could be observed before taking
further diagnostic or therapeutic steps.
In contrast to CTN, CEA did not prove to have any value
for prediction of morphologic progression. The heterogeneity of
CEA secretion in MTC has already been reported.10,11 Given
the variety of conditions that are associated with an elevated
CEA, this tumor marker appears inferior to CTN.
The present study underlines the fact that changes in tumor
markers not always reflect changes in tumor size. In analogy to
previously published studies, we could confirm a solid initial
decrease of both tumor markers upon treatment initiation with a
TKI with subsequent fluctuations in the majority of
patients.5,12,13 Compared to other trials investigating different
TKIs, a homogenous patient cohort exclusively under vande-
tanib followed-up up to almost 7 years was enrolled in this
study.5 The fluctuations in both tumor marker levels compared
to imaging-based findings clearly indicate that short-term vari-
ations may not reflect treatment response in MTC patients
undergoing vandetanib treatment.
This study has some limitations. First, only a small number
of patients could be included, thereby limiting statistical power
of analyses. Especially type II error concerning the value of
CEA cannot be excluded. Future studies in larger cohorts are
needed to fully elucidate the significance of CEA oscillations
for patient management. Second, this is a retrospective analysis
and a prospective approach is necessary to strengthen our
preliminary findings. Third, in almost 50% of subjects the
RET mutation status was not known and only 2 patients with
RET mutations could be enrolled.
In summary, in MTC patients undergoing treatment with
vandetanib, an increase of 40% in serum CTN levels predicts
objective PD with good accuracy and should trigger further
diagnostic work-up. Whereas all patients on TKI present with
oscillating tumor markers after an initial nadir, changes in
CTN< 40% can be monitored before taking further actions,
that is, discontinuing medication. CEA levels do not seem to be
of prognostic value for TKI monitoring. Larger prospective
studies are needed to fully elucidate the association between
tumor marker levels and tumor biology.
CONCLUSIONS
Tumor marker fluctuations in MTC patients undergoing
vandetanib treatment are a frequently observed phenomenon
and should not prompt drug discontinuation. A rise in CTN
Medicine  Volume 94, Number 45, November 201540% indicates tumor progression suggesting further diagnos-
tic work-up. The value of CEA in the setting of TKI response
monitoring seems to be rather limited.
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